Praxis Precision Medicines (PRAX) is down 5.6% today. Here is some analysis on what might have caused this price movement.
Analysis: There does not appear to be a fresh company-specific announcement tied directly to today’s decline. This could be because traders are taking profits after PRAX recently rallied toward new highs, while investors wait for the company’s next major regulatory catalysts later in 2026 and early 2027.
Details:
Praxis’s latest major corporate update came on August 6, when it reported second-quarter 2026 results and outlined progress across its late-stage pipeline.The company said the FDA had identified no major safety or efficacy concerns to date for ulixacaltamide and relutrigine during mid-cycle review, with target action dates set for January 29, 2027 and December 27, 2026, respectively.That same update also noted that the Phase 2/3 POWER1 study of vormatrigine in focal onset seizures did not meet its primary endpoint, even though a secondary measure showed a meaningful seizure reduction in some patients.Praxis ended June with about $1.4 billion in cash, cash equivalents, and marketable securities, enough to fund operations into 2028, so today’s move looks more tied to sentiment and positioning than to an obvious balance-sheet shock.Sources:
Praxis Precision Medicines, SEC, Nasdaq
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$PRAX Insider Trading Activity
$PRAX insiders have traded $PRAX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $PRAX stock by insiders over the last 6 months:
- JILL DESIMONE has made 0 purchases and 12 sales selling 11,600 shares for an estimated $3,611,334.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EARLY ACCESS
Receive PRAX Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$PRAX Hedge Fund Activity
We have seen 182 institutional investors add shares of $PRAX stock to their portfolio, and 150 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIS ALLAN GRAY LTD removed 942,692 shares (-38.1%) from their portfolio in Q2 2026, for an estimated $315,603,854
- POINT72 ASSET MANAGEMENT, L.P. removed 492,346 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $158,628,957
- INVESCO LTD. added 476,151 shares (+775.5%) to their portfolio in Q2 2026, for an estimated $159,410,593
- ASSENAGON ASSET MANAGEMENT S.A. removed 408,787 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $131,707,083
- RA CAPITAL MANAGEMENT, L.P. removed 373,787 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $125,140,149
- NORGES BANK added 342,615 shares (+7869.0%) to their portfolio in Q2 2026, for an estimated $114,704,075
- PRICE T ROWE ASSOCIATES INC /MD/ added 312,147 shares (+49.5%) to their portfolio in Q2 2026, for an estimated $104,503,694
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$PRAX Analyst Ratings
Wall Street analysts have issued reports on $PRAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 06/02/2026
To track analyst ratings and price targets for $PRAX, check out Quiver Quantitative's $PRAX forecast page.
$PRAX Price Targets
Multiple analysts have issued price targets for $PRAX recently. We have seen 10 analysts offer price targets for $PRAX in the last 6 months, with a median target of $537.5.
Here are some recent targets:
- Ami Fadia from Needham set a target price of $575.0 on 06/29/2026
- Leonid Timashev from RBC Capital set a target price of $449.0 on 06/18/2026
- Kambiz Yazdi from BTIG set a target price of $810.0 on 06/02/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $1201.0 on 06/02/2026
- David Hoang from Deutsche Bank set a target price of $374.0 on 06/02/2026
- Laura Chico from Wedbush set a target price of $162.0 on 06/02/2026
- Joel Beatty from Baird set a target price of $400.0 on 06/02/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Praxis Precision Medicines Slides as Investors Appear to Lock In Gains After Recent Rally
Praxis Precision Medicines (PRAX) is down 5.6% today. Here is some analysis on what might have caused this price movement.
Analysis: There does not appear to be a fresh company-specific announcement tied directly to today’s decline. This could be because traders are taking profits after PRAX recently rallied toward new highs, while investors wait for the company’s next major regulatory catalysts later in 2026 and early 2027.
Details:
Sources:
Praxis Precision Medicines, SEC, Nasdaq
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$PRAX Insider Trading Activity
$PRAX insiders have traded $PRAX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $PRAX stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PRAX Hedge Fund Activity
We have seen 182 institutional investors add shares of $PRAX stock to their portfolio, and 150 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$PRAX Analyst Ratings
Wall Street analysts have issued reports on $PRAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $PRAX, check out Quiver Quantitative's $PRAX forecast page.
$PRAX Price Targets
Multiple analysts have issued price targets for $PRAX recently. We have seen 10 analysts offer price targets for $PRAX in the last 6 months, with a median target of $537.5.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »